α-Klotho, hypoxia-inducible factor-2α, and oxidative stress in hemodialysis ‒ interactions with anemia, secondary hyperparathyroidism, and intradialytic hypotension
DOI:
https://doi.org/10.15584/ejcem.2026.3.6Keywords:
anemia, hemodialysis, hypoxia-inducible factor-2α, α-Klotho, oxidative stressAbstract
Introduction and aim. End-stage renal disease (ESRD) is associated with oxidative stress (OS) and hormonal disturbances linked to anemia, secondary hyperparathyroidism (SHPT), and intradialytic hypotension (IDH). This study evaluated the expression of α-Klotho (α-KL) and hypoxia-inducible factor-2α (HIF-2α) together with OS markers in hemodialysis (HD) patients and explored their interrelationships and associations with anemia, SHPT, and IDH.
Material and methods. Fifty HD patients and 50 healthy controls were evaluated for clinical and biochemical parameters, malondialdehyde (MDA), catalase (CAT) activity, and α-KL and HIF-2α expression. Correlation and network analyses were used to evaluate molecular interactions.
Results. Anemia, SHPT, and IDH were identified in 72%, 44%, and 18% of HD patients, respectively. Compared with controls, HD patients demonstrated significantly higher MDA levels and lower α-KL and HIF-2α expression, and CAT activity (all p<0.001). MDA positively correlated with parathyroid hormone (PTH) (r=0.26, p<0.01) and IDH (r=0.37, p<0.001), but inversely with hemoglobin (Hb) (r=−0.24, p<0.02) and CAT activity (r=−0.36, p<0.001). Lower α-KL and HIF-2α expression levels, together with reduced CAT activity, correlated positively with Hb (r=0.27–0.71) and inversely with PTH (r=−0.27 to−0.62) and IDH (r=−0.40 to−0.92) (all p<0.01). Positive intercorrelations were additionally found among α-KL, HIF-2α, and CAT (r=0.21–0.38, all p<0.05).
Conclusion. Reduced α-KL and HIF-2α expression together with altered OS markers were associated with anemia, SHPT, and IDH in HD patients. The close interrelationships observed among α-KL, HIF-2α, and OS markers may reflect an integrated molecular pattern linked to dialysis-related complications. Additional prospective studies are warranted to further elucidate these relationships.
Downloads
References
Lv JC, Zhang LX. Prevalence and disease burden of chronic kidney disease. Adv Exp Med Biol. 2019;1165:3-15. doi:10.1007/978-981-13-8871-2_1
Zahran A, Ahmed H, Issawi R. Prevalence and etiology of end-stage renal disease patients on maintenance hemodialysis. Menoufia Med J. 2020;33(3):766-771. doi:10.4103/mmj.mmj_395_18
Hashmi MF, Benjamin O, Lappin SL. End-stage renal disease. In: StatPearls [Internet]. StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499861/
Agarwal A, Anjum F. Hemodialysis. In: StatPearls [Internet]. StatPearls Publishing; 2026. Available from: https://www.ncbi.nlm.nih.gov/books/NBK563296/
Wang Y, Yu X. Stabilizing hypoxia-inducible factor to manage anemia in chronic kidney disease: from basic theory to clinical study. Kidney Dis (Basel). 2024;10(2):132-142. doi:10.1159/000536039
Hamrahian SM, Vilayet S, Herberth J, Fülöp T. Prevention of intradialytic hypotension in hemodialysis patients: current challenges and future prospects. Int J Nephrol Renovasc Dis. 2023;16:173-181. doi:10.2147/IJNRD.S245621
Liakopoulos V, Roumeliotis S, Zarogiannis S, Eleftheriadis T, Mertens PR. Oxidative stress in hemodialysis: Causative mechanisms, clinical implications, and possible therapeutic interventions. Semin Dial. 2019;32(1):58-71. doi:10.1111/sdi.12745
Rysz J, Franczyk B, Ławiński J, Gluba-Brzózka A. Oxidative stress in ESRD patients on dialysis and the risk of cardiovascular diseases. Antioxidants. 2020;9(11):1079. doi:10.3390/antiox9111079
Hong YA, Park CW. Catalytic antioxidants in the kidney. Antioxidants. 2021;10(1):130. doi:10.3390/antiox10010130
Piko N, Bevc S, Hojs R, Ekart R. The role of oxidative stress in kidney injury. Antioxidants. 2023;12(9):1772. doi:10.3390/antiox12091772
Fan Z, Wei X, Zhu X, et al. Correlation between soluble klotho and chronic kidney disease–mineral and bone disorder in chronic kidney disease: a meta-analysis. Sci Rep. 2024;14:4477. doi:10.1038/s41598-024-54812-4
Foresto-Neto O, da Silva ARPA, Cipelli M, Santana-Novelli FPR, Camara NOS. The impact of hypoxia-inducible factors in the pathogenesis of kidney diseases: a link through cell metabolism. Kidney Res Clin Pract. 2023;42(5):561-578. doi:10.23876/j.krcp.23.012
Kidney disease: Improving Global Outcomes (KDIGO) anemia work group. KDIGO 2026 Clinical practice guideline for the management of anemia in chronic kidney disease (CKD). Kidney Int. 2026;109(1S):S1-S99. doi:10.1016/j.kint.2025.06.006
Kidney disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl (2011). 2017;7(1):1-59. doi:10.1016/j.kisu.2017.04.001
Ye Y, Liu H, Chen Y, et al. Hemoglobin targets for the anemia in patients with dialysis-dependent chronic kidney disease: a meta-analysis of randomized, controlled trials. Ren Fail. 2018;40(1):671-679. doi:10.1080/0886022X.2018.1532909
Kidney Disease Outcomes Quality Initiative (KDOQI). Clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005;45(3 Pt 2):1-153. doi:10.1053/j.ajkd.2005.01.019
Valentini J, Grotto D, Paniz C, Roehrs M, Burg G, Garcia SC. The influence of the hemodialysis treatment time under oxidative stress biomarkers in chronic renal failure patients. Biomed Pharmacother. 2008;62(6):378-382. doi:10.1016/j.biopha.2007.10.017
Abogresha NM, Mohammed SS, Hosny MM, Abdallah HY, Gadallah AM, Greish SM. Diosmin mitigates cyclophosphamide induced premature ovarian insufficiency in rat model. Int J Mol Sci. 2021;22(6):3044. doi:10.3390/ijms22063044
Hadwan MH, Hussein MJ, Mohammed RM, et al. An improved method for measuring catalase activity in biological samples. Biol Methods Protoc. 2024;9(1):bpae015. doi:10.1093/biomethods/bpae015
Integrated DNA Technologies (IDT). Custom Primer Design. 2024. Available from: https://eu.idtdna.com/page/products/qpcr-and-pcr/custom-primers
National Center for Biotechnology Information (NCBI). Primer-BLAST. 2024. Available from: https://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi
Stothard P. The sequence manipulation suite: JavaScript programs for analyzing and formatting protein and DNA sequences. Biotechniques. 2000;28(6):1102-1104. doi:10.2144/00286ir01
San Millán RM, Martínez-Ballesteros I, Rementeria A, Garaizar J, Bikandi J. Online exercise for the design and simulation of PCR and PCR-RFLP experiments. BMC Res Notes. 2013;6:513. doi:10.1186/1756-0500-6-513
Casper J SM, Raney BJ, Perez G, Nassar LR, Lee CM, Hinrichs AS, et al. The UCSC Genome Browser database: 2026 update. Nucleic Acids Res. 2026;54(D1):D1331-D1335. doi:10.1093/nar/gkaf1250
Zalewski D, Bogucka-Kocka A. RQdeltaCT: an open-source R package for relative quantification of gene expression using delta Ct methods. Sci Rep. 2025;15(1):29762. doi:10.1038/s41598-025-11822-0
Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008;3(6):1101-1108. doi:10.1038/nprot.2008.73
Edmunds RC, McIntyre JK, Luckenbach JA, Baldwin DH, Incardona JP. Toward enhanced MIQE compliance: reference residual normalization of qPCR gene expression data. J Biomol Tech. 2014;25(2):54-60. doi:10.7171/jbt.14-2502-003
Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55(4):611-622. doi:10.1373/clinchem.2008.112797
Farag YMK, El-Sayed E. Global dialysis perspective: Egypt. Kidney360. 2022;3(7):1263-1268. doi:10.34067/kid.0007482021
Wang Y, Liu J, Fang Y, Zhou S, Liu X, Li Z. Estimating the global prevalence of secondary hyperparathyroidism in patients with chronic kidney disease: a systematic review. Front Endocrinol (Lausanne). 2024;15:1400891. doi:10.3389/fendo.2024.1400891
Arcentales-Vera K, Vera-Mendoza MF, Cevallos-Salas C, García-Aguilera MF, Fuenmayor-González L. Prevalence of cardiovascular instability during hemodialysis therapy in hospitalized patients: a systematic review and meta-analysis. Sci Prog. 2024;107(4):368504241308982. doi:10.1177/00368504241308982
Li SS, Sheng MJ, Sun ZY, Liang Y, Yu LX, Liu QF. Upstream and downstream regulators of Klotho expression in chronic kidney disease. Metabolism. 2023;142:155530. doi:10.1016/j.metabol.2023.155530
Li F, Ye X, Yang G, et al. Relationships between blood bone metabolic biomarkers and anemia in patients with chronic kidney disease. Ren Fail. 2023;45:2210227. doi:10.1080/0886022X.2023.2210227.
Razzaque MS. Interactions between FGF23 and vitamin D. Endocr Connect. 2022;11(10):e220239. doi:10.1530/EC-22-0239
Hu JW, Chu C, Shi T, Yan Y, Mu JJ. Effects of salt intervention on serum levels of Klotho influenced by salt sensitivity. J Clin Hypertens. 2020;22(11):2051-2058. doi:10.1111/jch.14044
Jung HJ, Pham TD, Su XT, et al. Klotho is highly expressed in the chief sites of regulated potassium secretion, and it is stimulated by potassium intake. Sci Rep. 2024;14:10740. doi:10.1038/s41598-024-61481-w
Liu L, Jia J, Cheng X, et al. The optimal cut-off values of Klotho for predicting all-cause and cardiovascular mortality among chronic kidney disease patients: results from NHANES. Sci Rep. 2024;14:4647. doi:10.1038/s41598-024-52701-4
Typiak M, Piwkowska A. Antiinflammatory actions of klotho: implications for therapy of diabetic nephropathy. Int J Mol Sci. 2021;22(2):956. doi:10.3390/ijms22020956
Lee SY, Park KH, Yu HG, et al. Controlling hypoxia-inducible factor-2α is critical for maintaining bone homeostasis in mice. Bone Res. 2019;7:14. doi:10.1038/s41413-019-0050-4
Mima A. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: advantages and disadvantages. Eur J Pharmacol. 2021;912:174583. doi:10.1016/j.ejphar.2021.174583
Navarro-García JA, Rodríguez-Sánchez E, Aceves-Ripoll J, et al. Oxidative status before and after renal replacement therapy: differences between conventional high-flux hemodialysis and online hemodiafiltration. Nutrients. 2019;11(11):2809. doi:10.3390/nu11112809
Stenvinkel P. Inflammation in end-stage renal disease: the hidden enemy. Nephrology (Carlton). 2006;11(1):36-41. doi:10.1111/j.1440-1797.2006.00541.x
Ebert T, Neytchev O, Witasp A, Kublickiene K, Stenvinkel P, Shiels PG. Inflammation and oxidative stress in chronic kidney disease and dialysis patients. Antioxid Redox Signal. 2021;35(17):1426-1448. doi:10.1089/ars.2020.8184
Kuro-o M. Klotho and aging. Biochim Biophys Acta. 2009;1790(10):1049-1058. doi:10.1016/j.bbagen.2009.02.005
Mima A. Inflammation and oxidative stress in diabetic nephropathy: new insights on its inhibition as new therapeutic targets. J Diabetes Res. 2013;2013:248563. doi:10.1155/2013/248563
Mima A, Yasuzawa T, King GL, Ueshima S. Obesity-associated glomerular inflammation increases albuminuria without renal histological changes. FEBS Open Bio. 2018;8(4):664-670. doi:10.1002/2211-5463.12400
Fu Y, Cao J, Wei X, Ge Y, Su Z, Yu D. Klotho alleviates contrast-induced acute kidney injury by suppressing oxidative stress, inflammation, and NF-κB/NLRP3-mediated pyroptosis. Int Immunopharmacol. 2023;118:110105. doi:10.1016/j.intimp.2023.110105
Liakopoulos V, Roumeliotis S, Gorny X, Eleftheriadis T, Mertens PR. Oxidative stress in patients undergoing peritoneal dialysis: a current review of the literature. Oxid Med Cell Longev. 2017;2017:3494867. doi:10.1155/2017/3494867
Lu J, Shi D, Zhao X, Xi M, Qi H, He Q. Comparative analysis of efficacy and prognosis of hemodialysis and peritoneal dialysis for end-stage renal disease: a meta-analysis. Comput Math Methods Med. 2022;2022:6007698. doi:10.1155/2022/6007698
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
